Roche ends Rocephin production in Switzerland, highlighting antibiotic supply challenges

letemps.ch (French)

Roche will cease production of its antibiotic Rocephin by 2030 due to unprofitability, signaling broader issues in antibiotic supply and innovation. The company is seeking a buyer for the drug, a widely used broad-spectrum antibiotic listed on the WHO's essential medicines list, but production is unlikely to continue in Europe. Rocephin, a significant past success for Roche, has been manufactured for over forty years. The global ceftriaxone market remains substantial.


With a significance score of 3.6, this news ranks in the top 7.2% of today's 30135 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Roche ends Rocephin production in Switzerland, highlighting antibiotic supply challenges | News Minimalist